

**REMARKS**

The undersigned thanks the Examiner for courtesies extended during the telephone interview of March 19, 2008. During this interview, the undersigned explained that claim 7 recites “sequentially releasing nucleotides” in step (d) and “identifying the released unlabeled nucleotides” in step (e). Arguably, there is no antecedent basis for “the released *unlabeled* nucleotides.” The Examiner suggested that the undersigned should file an amendment under 37 CFR 1.312 deleting the term “unlabeled” in claim 7.

In view of the above amendment, applicant believes the pending application is in condition for allowance.

Dated: March 20, 2008

Respectfully submitted,

By /Raj S. Davé/

Raj S. Davé

Registration No.: 42,465

DARBY & DARBY P.C.

P.O. Box 770

Church Street Station

New York, New York 10008-0770

(202) 639-7515

(212) 527-7701 (Fax)

Attorneys/Agents For Intel Corporation